The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Preventive Medicine Pub Date : 2024-01-30 eCollection Date: 2023-01-01 DOI:10.4103/ijpvm.ijpvm_12_22

Vahid Shaygannejad, Omid Mirmosayyeb, Sara Bagherieh, Parisa Shaygan, Mahsa Ghajarzadeh

{"title":"The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.","authors":"Vahid Shaygannejad, Omid Mirmosayyeb, Sara Bagherieh, Parisa Shaygan, Mahsa Ghajarzadeh","doi":"10.4103/ijpvm.ijpvm_12_22","DOIUrl":null,"url":null,"abstract":"Background: Fingolimod and interferons are used in the relapse form of multiple sclerosis (MS). The goal of this systematic review and meta-analysis was to evaluate the efficacy of fingolimod versus interferon in patients with MS. The systematic search was done in PubMed, Scopus, Embase, Web of Science, and Google Scholar.Methods: The references of included studies as well as conference abstracts were searched up to July 2021. The literature search revealed 8211 articles, and after deleting duplicates 5594 remained. For the meta-analysis, four studies were included. The standardized mean difference (SMD) of the Expanded Disability Status Scale (EDSS) after treatment (interferon vs fingolimod) was -0.06 (95% CI: -0.28, 0.17) (I2 = 80.2%, P = 0.002).Results: The SMD of the annual relapse rate (ARR) after treatment (interferon - fingolimod) was -0.08 (95% CI: -0.53, 0.36) (I2 = 95.5%, P < 0.001). The SMD of the ARR after treatment and before treatment in the interferon group was - 1.45, (95% CI: -1.55, -1.36) (I2 = 0, P = 0.3). The SMD of ARR after treatment and before treatment in the fingolimod group was - 1.3, (95% CI: -1.94, -0.65) (I2 = 97.4%, P < 0.001). Conclusions: The results of this systematic review show that efficacy of interferon and fingolimod in controlling relapse rate and disability is similar.","PeriodicalId":14342,"journal":{"name":"International Journal of Preventive Medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916411/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Preventive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijpvm.ijpvm_12_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Fingolimod and interferons are used in the relapse form of multiple sclerosis (MS). The goal of this systematic review and meta-analysis was to evaluate the efficacy of fingolimod versus interferon in patients with MS. The systematic search was done in PubMed, Scopus, Embase, Web of Science, and Google Scholar.

Methods: The references of included studies as well as conference abstracts were searched up to July 2021. The literature search revealed 8211 articles, and after deleting duplicates 5594 remained. For the meta-analysis, four studies were included. The standardized mean difference (SMD) of the Expanded Disability Status Scale (EDSS) after treatment (interferon vs fingolimod) was -0.06 (95% CI: -0.28, 0.17) (I² = 80.2%, P = 0.002).

Results: The SMD of the annual relapse rate (ARR) after treatment (interferon - fingolimod) was -0.08 (95% CI: -0.53, 0.36) (I² = 95.5%, P < 0.001). The SMD of the ARR after treatment and before treatment in the interferon group was - 1.45, (95% CI: -1.55, -1.36) (I² = 0, P = 0.3). The SMD of ARR after treatment and before treatment in the fingolimod group was - 1.3, (95% CI: -1.94, -0.65) (I² = 97.4%, P < 0.001). Conclusions: The results of this systematic review show that efficacy of interferon and fingolimod in controlling relapse rate and disability is similar.

查看原文本刊更多论文

芬戈莫德和干扰素在控制多发性硬化症患者残疾和复发率方面的疗效：系统回顾与元分析》。

背景：芬戈莫德和干扰素被用于多发性硬化症（MS）的复发治疗。本系统综述和荟萃分析旨在评估芬戈莫德与干扰素对多发性硬化症患者的疗效。方法：在PubMed、Scopus、Embase、Web of Science和Google Scholar上进行系统检索：方法：检索了截至 2021 年 7 月纳入研究的参考文献和会议摘要。文献检索共发现 8211 篇文章，删除重复文章后剩余 5594 篇。在荟萃分析中，共纳入了四项研究。结果显示，治疗（干扰素 vs 芬戈莫德）后扩展残疾状态量表（EDSS）的标准化平均差（SMD）为-0.06（95% CI：-0.28，0.17）（I2 = 80.2%，P = 0.002）：治疗（干扰素-芬戈莫德）后年复发率（ARR）的SMD为-0.08（95% CI：-0.53，0.36）（I2 = 95.5%，P < 0.001）。干扰素组治疗后与治疗前的ARR的SMD为-1.45，（95% CI：-1.55，-1.36）（I2 = 0，P = 0.3）。芬戈莫德组治疗后和治疗前的ARR的SMD为-1.3，（95% CI：-1.94，-0.65）（I2 = 97.4%，P < 0.001）。结论本次系统综述的结果表明，干扰素和芬戈莫德在控制复发率和残疾方面的疗效相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Preventive Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

3.20

自引率

4.80%

发文量

107

期刊介绍： International Journal of Preventive Medicine, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online journal with Continuous print on demand compilation of issues published. The journal’s full text is available online at http://www.ijpvmjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal will cover technical and clinical studies related to health, ethical and social issues in field of Preventive Medicine. Articles with clinical interest and implications will be given preference.

文献相关原料

公司名称	产品信息	采购帮参考价格